Wiley Bros. Aintree Capital, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $2.26 Billion
- Q2 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 597 shares of REGN stock, worth $688,502. This represents 0.03% of its overall portfolio holdings.
Number of Shares
597Holding current value
$688,502% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,461Shares Held
84.5MCall Options Held
907KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$10.4 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$9.74 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$9.55 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.58 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$5.35 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $124B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...